#JubilantIngrevia - Thread ⚡️

Global Integrated Life Science Products and Innovative Solutions Provider

Market Cap- 12,153Cr
FY21 Sales- 3,491Cr
Q1FY22 Sales- 1,145 Cr

~1,400 Total customers
3 Segments and 165+Products
60+ New products in the pipeline over the next 3-4 years
Ingrevia has strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services, and Therapeutics, Performance Polymers, Food Service, Auto, Consulting in Aerospace

FY21- EBITDA-627Cr(17.9%)

Ingrevia is born out of a union of ‘Ingredients’ and ‘Life’ (‘Vie’ in French)

Demerged from Jubilant Life sciences on 01.02.2021 and was listed on 19.03.2021

Increased focus on the LSI and Pharma Businesses, Capture Growth Opportunities and Unlock Value for Shareholders
Vision to double the Revenue by FY’26

Global presence through investments in India, USA, Canada, Europe, Singapore, China, Sri Lanka and Bangladesh

39% Of Revenue from Exports to 60 Countries

60 plants across 5 Manufacturing Units
Segments and Revenue Contribution:

Speciality Chemical - 32%
Nutrition & Health Solutions - 18%
Life Science Chemicals - 50%

How Vertical integration across the value chain enables cost-competitive advantage for Ingrevia 👇🏻
Specialty Chemicals Segment

FY21 Sales- 1,124Cr
EBITDA - 268Cr
72,000+ TPA Capacity

85 Products (Pyridines & Picolines, Cyanopyridines, Piperidines, Aminopyridines, Lutidines)
Amongst top 2 Globally in (Pyridine+Beta)
Globally #1 in 11 Pyridine Derivatives
Globally lowest cost producer of Pyridine offering significant long term advantage

Serving 15 of top 20 Global Pharma & 7 of top 10 Global Agrochem companies

Partner of Choice to ~420 global customers

Around 40% export in regulated markets leading to sustainable revenue
Investment of ~INR 550 Cr. by FY’24

Got 36 Products in Pipeline

Completely backward integrated range of products in Pyridines, Picolines, and its derivatives, globally places it in a unique position

Strong  RDT capabilities with expertise in 35 key technology platforms
Company is venturing into Diketene Chemistry platform to develop 12‑14 forward integrated products to cater to the needs of Pharma, Agro and other applications

Expect to start commercial production of diketene derivates  from Gajraula plant some time during Q4FY22.
Nutrition & Health Solutions – Segment
FY21 Sales- 630Cr
EBITDA - 130Cr

5 Nutrition Ingredients & 18+ branded solutions (For Animal Health)

Global largest producer of Niacinamide

19% Global market share in Vitamin B3 and  60% domestic share in Vitamin B4

Investment of ~INR 100 Cr. by FY’24
Got 18 Products in Pipeline.

Being fully Backward integrated and the lowest cost producer gives Ingrevia an advantage in expanding across geographies and adding more value-added products to its portfolio

Life Sciences Chemicals – Segment  

FY21 Sales- 1,738Cr
EBITDA - 236Cr
Q1FY22 Sales- 673Cr [103% YoY]

8 Products
Leadership in merchant market of Acetic Anhydride and Propionic Anhydride
9% Global market share in LSI & 10% domestic share in Speciality Alcohol
Among top suppliers of Fuel grade Ethanol to Oil Marketing

Investment of ~ INR 250 Cr. by FY’24
Got 7 Products in Pipeline.

Foraying into ENA facility to cater to distilleries markets

Multiple investments in the Segment to become the largest merchant marketer

Engaged in a long-term contract with feed stock suppliers, which protects from any unseen price shocks in sourcing key raw materials

Shift of manufacturing from China to India will encourage growth in various industrial applications in India
Research Development & Technology(RDT)-In addition to new product development, RDT unit focuses on Process Intensification, Absorption and Establishing Technologies on a commercial scale

3 RDT centers in Noida, Gajraula, Bharuch

90 highly qualified scientists(~20 PhDs)
35 Key technology platforms developed & commercialized to global standards

152 Patent applications; 94 Patents granted

39% Of Revenue from Exports to 60 Countries

Key financial highlights of FY21 and Q1FY22 - summarized

Life Sciences Chemical revenue grew by 103% YoY, driven by higher prices on account of favorable market conditions and pass-on of higher input cost of acetic acid
Jubilant Ingrevia with a diversified customer base, low cost of production and longstanding relationships with its customers, highly experienced management team, 60+ products in pipelines, 900Cr+ CAPEX, is ideally positioned to capitalise on the growth opportunities :)
Sources: Investor Presentation, Annual Report, Datacrunch

If you find this thread simple and helpful, please retweet, the first tweet of this thread :)

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Ajit Surya K

Ajit Surya K Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ajitsuryak

27 Jun
#Syngene - Thread⚡️

An integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform.

25+ years of unparalleled experience

@unseenvalue @AvadhMaheshwar2 @caniravkaria @Jitendra_stock @saketreddy @itsTarH
Syngene, a subsidiary of Biocon Ltd, was established in 1993 as India’s first Contract Research Organization.

CRO is a company that provides support to the pharma industry in the form of research services outsourced on a contract basis. CROs are designed to reduce costs.
Well-positioned to monetize a larger pie of the huge CRO market given its integrated capabilities, competitive strength, and cost advantage built over 20 years

>Moving from CRO to CRAMS(Contract research and manufacturing services) with commercial manufacturing

Read 19 tweets
19 Jun
HFCL - Bubble or 5G Opportunity - Thread⚡️

Leading manufacturer of optical fiber cables, optical transport, power electronics, and broadband equipment for the telecommunication industry

@Atulsingh_asan @caniravkaria @AvadhMaheshwar2  @saketreddy @Jitendra_stock  @AnishA_Moonka
#HFCL (2/n)

Wide Industries Served: Telecom, Defence, Railways, Security and Surveillance

8 Year Revenue CAGR: 25%

8 Year PAT CAGR: 20%

FY21 ROCE: 19.80%

D/E: 0.48x

R&D facilities at Bengaluru and Gurugram

Key Customers: Jio, BSNL, Tata, Airtel

Exporting to 30+ countries
#HFCL (3/n)
Telecom Segment:

Co looking to tap the ₹1-lakh crore 5G market opportunity in India, and exports to West Asia, South-East Asia and Europe

One of the largest telecom project service provider for Reliance Jio and is currently engaged in rolling out of 4G OFC Network
Read 21 tweets
12 Jun
Deepak Fertilisers - Thread⚡️

Established in 1979, Deepak Fertilisers And Petrochemicals Corporation Limited(DFPCL) is one of India’s leading producers of fertilisers and industrial chemicals.

@caniravkaria @saketreddy @nakulvibhor @Jitendra_stock @AvadhMaheshwar2 @TSG_Capital

Set up by Chimanlal K Mehta [Founder of Deepak Nitrite] as an ammonia manufacturer, the Rs 4,000 cr DFPCL is today run by his youngest son Sailesh Mehta, who is chairman & managing director of the company.  

The Company is headquartered in Pune.

FY21 Sales - 5,800 cr
Revenue Breakup -Chemicals - 54%; Fertilisers - 46%
Profit- 944 cr
Chemicals contributed to 80% of the profits
Promoters hold.- 55.80%
D/E - 0.88
Shares Pledged -15.3%

>>Promoters and FIIs have increased holdings in the last quarter
Read 15 tweets
2 Jun
Insurance Industry - Indian Perspective - Thread 🧵

Growth Drivers :

Increasing Life Expectancy
Favorable Savings
Greater employment

@Atulsingh_asan @caniravkaria  @Coolfundoo @saketreddy @Jitendra_stock

The growing interest in insurance among people, innovative products, and distribution channels are aiding growth.

High Penetration for digital platforms, with an average of 90% using digital platforms at least once a week

HDFCLIFE - 49% share of digital new business in FY20.
In FY21 (until February 2021), the premium from the new business of life insurance companies in India stood at US$ 31.9 billion.

Basic Terms:

Insurance penetration - Percentage of insurance premium to GDP

Insurance density - Ratio of insurance premium to population.
Read 19 tweets
1 Jun
ITC FMCG - Segment Update.

Segment Revenue - 14728 cr

Growth - 14.7%

120+ innovative products launched – hygiene, health & wellness, naturals, convenience

Segment EBITDA up 44% in FY21

ITC e-commerce FMCG Sales doubled: now accounts for ~5% of revenue

Increasing digital adoption by Traditional Trade & Collaboration with Online-delivery platforms

Rural markets continue to grow ahead of Urban/Metro
Demand for Health & Hygiene, Immunity, Ayurveda products remained elevated; albeit at lower levels Vs. H1

Higher crude and vegetable oil prices drive an increase in input costs

Snacks and Beverages category post-double-digit growth in Q4
Read 5 tweets
27 Feb
#IEX Thread⚡️

IEX - First and Largest Energy exchange in India (98% Market Share - Monopoly!!)

Automated trading platform for physical delivery of electricity, renewable power, energy certificates.

@Atulsingh_asan @caniravkaria @Coolfundoo @saketreddy @Jitendra_stock
#IEX (2/n)

ROCE 5Yr - 63.9 %; ROE 5Yr - 45.0%

Zero Debt, Consistent FCF Generation

FII Holding - 5% in 2017 to 30% in 2020

Electricity CAGR 32% [CERC]

Revenue Breakup : 80% - Transaction Charges; 6% - Annual Subscription

Customer Base: 4000+ Industries

#IEX (3/n)

Contracts in Indian Power Market: Long Term and Short Term

Long Term via Power Purchase Agreements-  90% of Total Power Market

The target for IEX - Short Term Contracts: 10.3% of the total power market!

50.2% of Short Term Exchange via platforms

Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!